PubMed Health⌕ Search

Biomedical subjects

S Delons

Publications and source records attributed to S Delons.

52 records · Page 3Linked to original sources
PubMed1977

Prevention of hepatitis B in hemodialysis patients using hepatitis B immunoglobulin. A controlled study.

In a controlled study, the protection effect of hepatitis B immune globulin (HBIG) was evaluated in patients hemodialyzed for less than one month in two collaborating units. Fifteen randomly selected patients received HBIG at five to eight week intervals throughout the study, and 13 other control patients received no immunoglobulin. During a follow-up period of 14 to 30 months, none of the HBIG-treated and 12 of the control patients developed evidence of exposure to virus B hepatitis, including 10 with HBs Ag antigenemia (p is less than 0.001): five of these remained persistently antigen positive. Evidence of non-B hepatitis was found in 8 HBIG-treated and in 3 non-treated patients. Only two HBIG-treated patients developed active antibodies against hepatitis B surface antigen. Thus, HBIG seems effective in preventing hepatitis B in hemodialysis patients, provided the interval between two injections is not greater than two months. However, prolonged administration of HBIG may impair passive-active immunization to hepatitis B virus.

Adult↗
PubMedDate not supplied

Attempt to prevent hepatitis by using specific anti-HBs immunoglobulin.

Sixteen batches of specific anti-HBs immunoglobulin have been prepared from December 1970 up to now. They were used in an attempt to prevent hepatitis B: (1) By a single injection, within seven days, in patients exposed by HBs Ag-positive blood transfusion: with a dose of 0.16 ml/kg, two hepatitis B cases were observed among 29 followed up patients out of 43 cases; with a dose of 0.5 ml/kg, no hepatitis was reported to us in the next 26 patients. (2) By a single injection, within seven days, in laboratory and hospital personnel accidentally contaminated. With a dose of 0.08 ml/kg administered to more than 1000 persons, an excellent protection was observed. (3) By injections repeated every five weeks during the first four months, then more widely spaced during the following months, in hemodialysis units staff. The attack rate of clinical hepatitis B was reduced from about 44 per cent to 0 per cent. No hepatitis case was observed in 90 persons protected from four to 26 months. In a control group (eight subjects) three hepatitis B cases occurred (37 per cent).

Accidents↗
PubMedDate not supplied

Plasma histamine levels and kinetics in chronic hemodialysis patients.

Pruritus is frequently observed in hemodialyzed patients; its etiology seems to be multifactorial. Increased plasma histamine levels have been reported in chronic renal failure. As histamine is a potent inducer of pruritus. The authors investigated its concentrations and kinetics in plasma of stable hemodialyzed patients.

Adult↗